Harrow had its Relative Strength (RS) Rating upgraded from 68 to 72 Thursday — a welcome improvement, but still short of the 80 or better score you prefer to see.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's proprietary rating identifies share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
History shows that the best stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Harrow can continue to show renewed price strength and clear that threshold.
Harrow is now considered extended and out of buy range after clearing a 20.31 buy point in a third-stage consolidation. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line.
Harrow reported 0% earnings growth last quarter. Revenue rose 38%.
The company earns the No. 147 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
